表 3.
不同组间患者的治疗疗效汇总
Efficacy summary by cohorts
| Items | Atezolizumab (n=100) | Atezolizumab+ gemcitabine+ cisplatin (n=20) | |||||
| EC (n=20) | GC (n=20) | HCC (n=20) | NPC (n=20) | PK (n=20) | NSCLC (n=20) | ||
| ORR, objective response rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; DCR, disease control rate; PD, progressive disease; CI, confidence interval; NE, not evaluable; NA, not applicable; Other abbreviations as in Figure 1 and Table 1. a, DCR is calculated by taking the sum of CR, PR, and SD. | |||||||
| ORR (95%CI)/% | 10.0 (1.23-31.70) | 15.0 (3.21-37.89) | 10.0 (1.23-31.70) | 5.0 (0.13-24.87) | 10.0 (1.23-31.70) | 40.0 (19.12-63.95) | |
| CR, n(%) | 0 | 0 | 0 | 0 | 0 | 0 | |
| PR, n(%) | 2 (10.0) | 3 (15.0) | 2 (10.0) | 1 (5.0) | 2 (10.0) | 8 (40.0) | |
| SD, n(%) | 6 (30.0) | 7 (35.0) | 10 (50.0) | 12 (60.0) | 7 (35.0) | 10 (50.0) | |
| DCRa, n(%) | 8 (40.0) | 10 (50.0) | 12 (60.0) | 13 (65.0) | 9 (45.0) | 18 (90.0) | |
| PD, n(%) | 7 (35.0) | 7 (35.0) | 7 (35.0) | 7 (35.0) | 11 (55.0) | 1 (5.0) | |
| NE, n(%) | 0 | 0 | 0 | 0 | 0 | 0 | |
| Missing, n(%) | 5 (25.0) | 3 (15.0) | 1 (5.0) | 0 | 0 | 1 (5.0) | |
| Median DOR (95%CI)/months | 14.4 (8.0-20.8) | 18.4 (NE) | NE (6.9-NE) | 8.3 (NE) | NA | NE (5.6-NE) | |
| Median PFS (95%CI)/months | 1.4 (1.4-2.8) | 2.7 (1.4-4.4) | 2.8 (1.4-7.8) | 3.5 (1.4-7.0) | NA | 5.8 (5.5-9.6) | |
| Median OS (95%CI)/months | 4.8 (2.1-10.9) | 9.7 (3.7-27.6) | 7.8 (4.7-NE) | 13.9 (8.2-21.3) | NA | NE (9.6-NE) | |
| 6-month OS rate (95%CI)/% | 40 (19-61) | 52 (29-75) | 61 (39-84) | 90 (77-100) | NA | 89 (74-100) | |
| 1-year OS rate (95%CI)/% | 25 (6-44) | 37 (13-61) | 43 (19-66) | 57 (34-80) | NA | 66 (27-100) | |
| Duration of follow-up/months, M (Range) | 4.76 (0.3-29.9) | 7.41 (1.2-29.2) | 12.16 (0.7-29.2) | 14.93 (1.7-26.3) | 15.21 (2.4-27.5) | 6.95 (0.8-14.6) | |